April 27, 2026 —
AviadoBio has entered a strategic licensing agreement with Apertura Gene Therapy to access TfR1 CapX™, a next-generation Adeno-associated virus (AAV) capsid engineered for intravenous delivery across the blood-brain barrier (BBB), expanding momentum in the race to develop systemically delivered CNS gene therapies.
The deal centers on one of the most significant challenges in neurogenetic medicine: efficiently delivering therapeutics broadly throughout the brain and spinal cord after IV administration.
TfR1 CapX is designed to target human transferrin receptor 1 (hTfR1), a clinically validated receptor used as a “brain shuttle” to facilitate BBB transport. Preclinical studies have shown widespread neuronal and astrocyte transduction throughout the CNS, making the capsid a potentially important tool for diseases that require broad CNS distribution.
AviadoBio plans to pair the capsid with its proprietary vMiX™ RNAi platform, which uses AAV-delivered gene silencing to drive durable knockdown of disease-causing genes following a single administration.
The lead application under the collaboration is AVB-406, an investigational intravenous AAV-miRNA therapy targeting MAPT (tau) for Alzheimer’s disease and other tauopathies.
This collaboration sits at the intersection of two major trends shaping next-generation AAV therapeutics:
1. Engineered capsids for systemic CNS delivery
Novel capsids capable of crossing the blood-brain barrier remain one of the field’s biggest priorities, particularly for neurodegenerative diseases where localized delivery approaches may be limiting.
2. AAV beyond gene replacement
Rather than traditional transgene replacement, AVB-406 highlights how AAV is increasingly being deployed as a delivery vehicle for RNA interference and gene silencing.
Together, that combination could enable one-time IV-delivered, broadly distributed CNS gene silencing therapies—a potentially transformative approach for complex disorders such as Alzheimer’s disease.
The agreement also reflects rising industry emphasis on capsid innovation as a differentiator, where vector engineering is becoming as strategically important as payload biology.
AviadoBio will present three oral presentations on AVB-406 at the upcoming American Society of Gene & Cell Therapy Annual Meeting, including preclinical, translational, and manufacturing data—signaling growing maturity around both the therapeutic program and scalable production strategy.
For the AAV field, the deal underscores growing momentum around BBB-crossing vectors, IV CNS delivery, and RNAi-enabled genetic medicines as important frontiers in neurodegenerative drug development.
